BRPI0920135A2 - imidazopiridazinacarbonitrilos úteis como inibidores de quinase - Google Patents
imidazopiridazinacarbonitrilos úteis como inibidores de quinaseInfo
- Publication number
- BRPI0920135A2 BRPI0920135A2 BRPI0920135A BRPI0920135A BRPI0920135A2 BR PI0920135 A2 BRPI0920135 A2 BR PI0920135A2 BR PI0920135 A BRPI0920135 A BR PI0920135A BR PI0920135 A BRPI0920135 A BR PI0920135A BR PI0920135 A2 BRPI0920135 A2 BR PI0920135A2
- Authority
- BR
- Brazil
- Prior art keywords
- imidazopyridazinecarbonitriles
- useful
- kinase inhibitors
- kinase
- inhibitors
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Mobile Radio Communication Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10404508P | 2008-10-09 | 2008-10-09 | |
| PCT/US2009/059968 WO2010042699A1 (en) | 2008-10-09 | 2009-10-08 | Imidazopyridazinecarbonitriles useful as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0920135A2 true BRPI0920135A2 (pt) | 2019-09-24 |
Family
ID=41718919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0920135A BRPI0920135A2 (pt) | 2008-10-09 | 2009-10-08 | imidazopiridazinacarbonitrilos úteis como inibidores de quinase |
Country Status (27)
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8389527B2 (en) * | 2008-02-06 | 2013-03-05 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
| TWI491610B (zh) * | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| WO2012068073A2 (en) | 2010-11-15 | 2012-05-24 | University Of Florida Research Foundation, Inc. | Therapeutic and diagnostic applications targeting tnk-1 |
| US20130303532A1 (en) | 2010-12-17 | 2013-11-14 | Bayer Intellectual Property Gmbh | Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders |
| CN103370322B (zh) | 2010-12-17 | 2016-02-10 | 拜耳知识产权有限责任公司 | 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪 |
| CA2821817A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Intellectual Property Gmbh | Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| US20140323519A1 (en) * | 2011-04-26 | 2014-10-30 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as b-raf inhibitors for treatment of cancer |
| ES2605946T3 (es) | 2012-03-14 | 2017-03-17 | Bayer Intellectual Property Gmbh | Imidazopiridazinas sustituidas |
| US20150087687A1 (en) | 2012-03-23 | 2015-03-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| TW201414737A (zh) * | 2012-07-13 | 2014-04-16 | 必治妥美雅史谷比公司 | 作爲激酶抑制劑之咪唑并三□甲腈 |
| WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| TW201437211A (zh) * | 2013-03-01 | 2014-10-01 | Bayer Pharma AG | 經取代咪唑并嗒□ |
| JP2016526534A (ja) | 2013-06-11 | 2016-09-05 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換トリアゾロピリジンのプロドラッグ誘導体 |
| WO2015013579A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Compositions to improve the therapeutic benefit of bisantrene |
| TW201542550A (zh) * | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
| AR097543A1 (es) * | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
| GB201403536D0 (en) * | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| JP6843135B2 (ja) | 2015-11-18 | 2021-03-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物 |
| CN109562111B (zh) | 2016-06-24 | 2023-04-04 | 北极星药业股份有限公司 | Ck2抑制剂，其组合物及方法 |
| MA45940B1 (fr) * | 2016-08-10 | 2024-12-31 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique |
| KR102611856B1 (ko) | 2016-11-17 | 2023-12-07 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn-알파의 이미다조피리다진 조정제 |
| WO2018183964A1 (en) | 2017-03-30 | 2018-10-04 | Genentech, Inc. | Isoquinolines as inhibitors of hpk1 |
| US11339157B1 (en) | 2017-10-24 | 2022-05-24 | Bayer Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
| EP3719011B1 (en) | 2017-12-29 | 2023-03-29 | Jiangsu Flag Chemical Industry Co., Ltd. | Pyrazole amide compound having pesticidal activity and use thereof |
| CN109988150B (zh) | 2017-12-29 | 2022-04-12 | 江苏中旗科技股份有限公司 | N-烷基-n-氰基烷基苯甲酰胺类化合物及其应用 |
| WO2019128871A1 (zh) | 2017-12-29 | 2019-07-04 | 江苏中旗科技股份有限公司 | N-烷基-n-氰基烷基苯甲酰胺类化合物及其应用 |
| MX2020007797A (es) * | 2018-01-29 | 2020-09-18 | Merck Patent Gmbh | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. |
| SG11202012922VA (en) | 2018-07-09 | 2021-01-28 | Boehringer Ingelheim Animal Health Usa Inc | Anthelminthic heterocyclic compounds |
| US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
| EP3935058B1 (en) | 2019-03-05 | 2024-08-21 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| CA3133100A1 (en) | 2019-03-19 | 2020-09-24 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic aza-benzothiophene and aza-benzofuran compounds |
| CN114127064B (zh) | 2019-04-24 | 2023-12-26 | 拜耳股份有限公司 | 4H-吡咯并[3,2-c]吡啶-4-酮化合物 |
| US12403135B2 (en) | 2019-04-24 | 2025-09-02 | Bayer Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
| EP3959212A1 (en) | 2019-04-24 | 2022-03-02 | Bayer Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one compounds |
| EP4126861B1 (en) | 2020-03-31 | 2025-06-18 | Bayer Aktiengesellschaft | 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer |
| CR20220665A (es) | 2020-05-29 | 2023-07-19 | Boehringer Ingelheim Pharma | Compuestos heterocíclicos como anthelmínticos |
| US20240158401A1 (en) * | 2021-02-03 | 2024-05-16 | Sanofi | DERIVATIVES OF IMIDAZO[4,5-d]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| PE20250675A1 (es) | 2021-11-01 | 2025-03-04 | Boehringer Ingelheim Vetmedica Gmbh | Compuestos de pirrolopiridazina como antihelminticos |
| MX2024009105A (es) * | 2022-01-25 | 2024-09-18 | Kinnate Biopharma Inc | Inhibidores de las cinasas cdk4/6. |
| WO2024039767A1 (en) * | 2022-08-18 | 2024-02-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Imidazo[1,2-b]pyridazine inhibitors of cyclin-dependent kinases |
| CN115947756B (zh) * | 2022-12-13 | 2025-08-01 | 西湖大学 | 一种芳基卤代物和多氟烷基醇直接偶联合成多氟烷基芳基醚的方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1227554A (zh) | 1996-08-28 | 1999-09-01 | 辉瑞大药厂 | 取代的6,5－杂二环衍生物 |
| JP3729343B2 (ja) | 2000-04-27 | 2005-12-21 | アステラス製薬株式会社 | 縮合ヘテロアリール誘導体 |
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| US7824851B2 (en) | 2002-11-15 | 2010-11-02 | Idenix Pharmaceuticals, Inc. | 2′-branched nucleosides and Flaviviridae mutation |
| KR20060110344A (ko) * | 2003-12-31 | 2006-10-24 | 쉐링-프라우 리미티드 | 이미다조[1,2-ｂ]피리다진 유도체를 사용하여 동물에서기생충을 방제하는 방법 |
| CA2555263A1 (en) | 2004-02-12 | 2005-09-01 | Neurogen Corporation | Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands |
| CN101048158A (zh) * | 2004-08-13 | 2007-10-03 | 健泰科生物技术公司 | 利用atp的酶的噻唑－类抑制剂 |
| JPWO2006070943A1 (ja) * | 2004-12-28 | 2008-06-12 | 武田薬品工業株式会社 | 縮合イミダゾール化合物およびその用途 |
| US20070185063A1 (en) | 2005-08-23 | 2007-08-09 | Idenix Pharmaceuticals, Inc. | Seven-membered ring nucleosides |
| WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| CL2007002261A1 (es) * | 2006-08-04 | 2008-05-02 | Takeda Pharmaceutical | Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer. |
| EP1900739A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Diazolodiazine derivatives as kinase inhibitors |
| CA2663091A1 (en) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | Modulators of interleukin-1 receptor-associated kinase |
| WO2008029152A2 (en) | 2006-09-08 | 2008-03-13 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| EP1911451A1 (en) * | 2006-10-10 | 2008-04-16 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Protein-kinase CK2 inhibitors and their therapeutic applications |
| CA2667960A1 (en) * | 2006-10-30 | 2008-05-08 | Novartis Ag | Imidazopyridazines as pi3k lipid kinase inhibitors |
| AR066477A1 (es) * | 2007-05-09 | 2009-08-19 | Novartis Ag | Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido |
| US8389527B2 (en) * | 2008-02-06 | 2013-03-05 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
| TWI491610B (zh) * | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
-
2009
- 2009-10-01 TW TW098133429A patent/TWI491610B/zh not_active IP Right Cessation
- 2009-10-08 US US12/575,589 patent/US8252795B2/en active Active
- 2009-10-08 EA EA201100580A patent/EA018163B1/ru not_active IP Right Cessation
- 2009-10-08 KR KR1020117010394A patent/KR20110075010A/ko not_active Ceased
- 2009-10-08 CA CA2739782A patent/CA2739782A1/en not_active Abandoned
- 2009-10-08 DK DK09740573.2T patent/DK2350081T3/da active
- 2009-10-08 PE PE2011000814A patent/PE20110411A1/es not_active Application Discontinuation
- 2009-10-08 MX MX2011003304A patent/MX2011003304A/es active IP Right Grant
- 2009-10-08 SI SI200930729T patent/SI2350081T1/sl unknown
- 2009-10-08 WO PCT/US2009/059968 patent/WO2010042699A1/en not_active Ceased
- 2009-10-08 EP EP09740573.2A patent/EP2350081B1/en not_active Not-in-force
- 2009-10-08 JP JP2011531168A patent/JP5560278B2/ja not_active Expired - Fee Related
- 2009-10-08 PT PT97405732T patent/PT2350081E/pt unknown
- 2009-10-08 HR HRP20130787AT patent/HRP20130787T1/hr unknown
- 2009-10-08 BR BRPI0920135A patent/BRPI0920135A2/pt not_active IP Right Cessation
- 2009-10-08 NZ NZ591712A patent/NZ591712A/xx not_active IP Right Cessation
- 2009-10-08 ES ES09740573T patent/ES2426951T3/es active Active
- 2009-10-08 CN CN200980149133.2A patent/CN102245609B/zh not_active Expired - Fee Related
- 2009-10-08 PL PL09740573T patent/PL2350081T3/pl unknown
- 2009-10-08 AU AU2009302360A patent/AU2009302360B2/en not_active Ceased
- 2009-10-09 AR ARP090103910A patent/AR073818A1/es unknown
-
2011
- 2011-03-10 IL IL211693A patent/IL211693A/en not_active IP Right Cessation
- 2011-03-31 ZA ZA2011/02423A patent/ZA201102423B/en unknown
- 2011-04-07 CO CO11043111A patent/CO6361936A2/es active IP Right Grant
- 2011-04-07 CL CL2011000777A patent/CL2011000777A1/es unknown
-
2012
- 2012-07-19 US US13/552,795 patent/US20120283241A1/en not_active Abandoned
-
2013
- 2013-09-30 CY CY20131100844T patent/CY1114539T1/el unknown
- 2013-10-02 SM SM201300109T patent/SMT201300109B/xx unknown
-
2014
- 2014-02-27 US US14/191,861 patent/US9371328B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR25C1006I1 (fr) | Inhibiteurs de pyrazolyl-quinoxaline kinase | |
| CY2020024I2 (el) | Αναστολεiς βητα-λακταμασων | |
| BRPI0920135A2 (pt) | imidazopiridazinacarbonitrilos úteis como inibidores de quinase | |
| BRPI0913879A2 (pt) | fenilpirazinonas como inibidores de quinase | |
| CY2019027I1 (el) | Παραγωγα φωσφορου ως αναστολεις κινασης | |
| BRPI0913580A2 (pt) | pirrolopiridinas como inibidores de quinase | |
| BRPI0914652A2 (pt) | compostos e composições como inibidores de quinase | |
| BRPI0908494A2 (pt) | Inibidores de pirrolopirazina quinase | |
| BRPI0811065A2 (pt) | Indazóis 5-heteroaril substituídos como inibidores de quinase | |
| BRPI0912475A8 (pt) | compostos como inibidores de quinase | |
| BRPI0906973A2 (pt) | Compostos e composições como inibidores de cinase. | |
| BRPI0812825A2 (pt) | Derivados ftalazinona como inibidores de parp-1 | |
| BRPI0912668A2 (pt) | composto e composições como inibidores de quinase | |
| ATE519763T1 (de) | Pyrrolopyrazin-kinasehemmer | |
| BRPI0918846A2 (pt) | inibidores de cinase heterocíclica | |
| BRPI0906838A2 (pt) | Pirimidinas como inibidores de quinase | |
| EP2498607A4 (en) | Kinase Inhibitors | |
| EP2493313A4 (en) | Kinase Inhibitors | |
| EP2519517A4 (en) | TYPE II RAF KINASE INHIBITORS | |
| BRPI0922937A2 (pt) | inibidores de pirrolopirazinil uréia quinase | |
| BRPI0911228A2 (pt) | compostos e composições como inibidores de proteínas quinase | |
| BRPI0814797A2 (pt) | Inibidores dna-pk | |
| BRPI0908849A2 (pt) | Composto e composições como c-kit e inibidores de pdgfr quinase | |
| BRPI0820544A2 (pt) | 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase | |
| EP2558099A4 (en) | Kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |